Sponsors

Advancing early detection of pancreatic cancer

Immunovia has received final approval to begin patient testing for the IMMray PanCan-d test – the first blood test on the market dedicated to the early detection of pancreatic cancer.

Approval was received from the Massachusetts Department of Public Health on 3 August. The test recognises biomarker signatures and has the potential to increase the survival of patients by detecting pancreatic cancer when surgical resection is still possible.

IMMray is a technology platform for developing bioinformatics-assisted, blood-based tests with the potential to detect complex diseases earlier and with higher accuracy. The first application of this technology is IMMray PanCan-d, which is a blood test designed for early detection of pancreatic cancer (PDAC stage I & II). The test is offered exclusively as a laboratory developed test (LDT) by Immunovia.

Immunovia’s test platform is based on advanced bioinformatics, used to single out a few relevant biomarkers to form a unique disease fingerprint for complex diseases such as pancreatic cancer, other cancers and autoimmune diseases.

www.immunoviainc.com

Latest Issues

GenQA at ESCV 2025

Thessaloniki Concert Hall
17 September, 2025

IBMS Congress

The International Convention Centre (ICC), Birmingham
22-25 September, 2025

Diagnostics North East Conference 2025

The Catalyst, Newcastle
3 October